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Abstract
Background: Myanmar is currently classified as a high burden dengue country in the Asian Pacific region. The Myanmar
vector-borne diseases control (VBDC) program has collected data on dengue and source reduction measures since 1970,
and there is a pressing need to collate, analyze, and interpret this information. The aim of this study was to describe the
burden of hospital-based dengue disease, dengue control measures, and serotype patterns in Myanmar between 2011
and 2015.
Methods: This was a cross-sectional study using annual records from the Dengue Fever/Dengue Hemorrhagic Fever
Prevention and Control Project in Myanmar.
Results: Between 2011 and 2015, there were a total of 89,832 cases and 393 deaths in hospitals, with 97% of cases
being in children. In 2013 and 2015, there was an increased number of cases, respectively at 21,942 and 42,913, while
during the other 3 years, numbers ranged from 4738 to 13,806. The distribution of dengue deaths each year mirrored
the distribution of cases. Most cases (84%) occurred in the wet season and 54% occurred in the delta/lowlands. Case
fatality rate (CFR) was highest in 2014 at 7 per 1000 dengue cases, while in the other years, it ranged from 3 to 5 per
1000 cases. High CFR per 1000 were also observed in infants < 1 year (CFR = 8), adults ≥ 15 years (CFR = 7), those with
disease severity grade IV (CFR = 17), and those residing in hilly regions (CFR = 9). Implementation and coverage of
dengue source reduction measures, including larval control, space spraying, and health education, all increased between
2012 and 2015, although there was low coverage of these interventions in households and schools and for water
containers. In the 2013 outbreak, dengue virus serotype 1 predominated, while in the 2015 outbreak, serotypes 1, 2,
and 4 were those mainly in circulation.
Conclusion: Dengue is a serious public health disease burden in Myanmar. More attention is needed to improve
monitoring, recording, and reporting of cases, deaths, and vector control activities, and more investment is needed for
programmatic research.
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Background
Dengue fever is a mosquito-borne tropical disease that
usually lasts 2 to 7 days and is caused by the dengue virus
[1, 2]. In a small proportion of cases, the disease develops
into (a) life-threatening dengue hemorrhagic fever (DHF)
or (b) dengue shock syndrome (DSS). There are no spe-
cific drugs for the treatment of dengue, which is merely
supportive. The infection is spread by two species of Aedes
mosquito, Aedes aegypti (the principal vector) and Aedes
albopictus. The virus has four distinct, but closely related,
serotypes. Recovery from infection by one serotype pro-
vides lifelong immunity against that particular serotype.
Cross-immunity to the other serotypes occurs, but this is
only partial and temporary, and subsequent infections by
other serotypes increase the risk of that person developing
severe dengue complications such as DHF or DSS. A
novel vaccine (Dengvaxia) has been developed and has
been shown to be effective [3–5], but, although it is
licensed and in use, it is not yet fully deployed. Thus,
prevention is currently focused on reducing the mosquito
habitats and limiting human exposure to mosquito bites.
The incidence of dengue has grown dramatically around
the world in recent decades, with a 30-fold increase in
estimated cases in the last 50 years. On the basis of popu-
lation data and geostatistical models, the burden of
dengue infections globally is estimated at 390 million
infections per year, with 96 million of those presenting
clinically with mild, moderate, or severe disease [6, 7].
Further modeling suggests that 3.9 billion people living in
128 countries are at risk of infection with dengue viruses
[7]. In the World Health Organization (WHO) South-East
Asia region and Western Pacific Region, some 1.8 billion
people (more than 70% of the population) are at risk of
dengue, and this poses a substantial economic and disease
burden on these countries [1, 8].
To combat this growing problem in the region, the
Asia Pacific Dengue Strategic Plan (2008–2015) was de-
veloped with the goal of reversing the rising trend of
dengue cases by enhancing preparedness to detect,
characterize, and contain outbreaks rapidly and to stop
the spread of the virus to new areas [9]. Progress is be-
ing made with implementation combined with oper-
ational and surveillance response research [10].
Myanmar has seen an escalating number of cases of
dengue in the last 10 years, despite vector control efforts,
and is currently classified as a high burden dengue coun-
try in the Asian Pacific region [8]. There is a prevention
and treatment program which works as follows. Patients
with dengue are diagnosed in hospitals of all States/Re-
gions of Myanmar, with the diagnosis mainly based on
clinical criteria according to 2011 WHO guidelines [11].
Rapid diagnostic test kits for dengue are available, but
these are in limited supply and are rarely used. Serotype
confirmation can be carried out, but this requires
polymerase chain reaction (PCR), which is available at the
National Health Laboratory under the Department of
Public Health and the Department of Medical Research.
PCR is done mainly through research and surveillance in
response to outbreaks, but each year, children with dengue
are also asked to provide specimens so that information
can be obtained about circulating serotypes [12, 13]. Once
patients are notified with dengue, source reduction mea-
sures (mainly control of mosquito larvae and adult mos-
quitoes) are implemented along with health education and
social mobilization [14].
The Myanmar vector-borne diseases control (VBDC)
program has collected data on dengue cases, dengue
deaths, and vector control measures since 1970, but
there is a pressing need to collate, analyze, and inter-
pret this information and, particularly, to generate
location-specific spot maps of the burden of dengue in
the country. For a resource-constrained country like
Myanmar, this information will enhance cost-effective
mitigation strategies and help to promote community
engagement for dengue control. The aim of this study,
therefore, was to describe the burden of dengue disease,
dengue control measures, and serotype patterns in
Myanmar over a 5-year period between 2011 and 2015.
Specific objectives were to describe for each year: (i)
public hospital-reported cases of dengue and deaths,
stratified by age, gender, urban/rural residence, disease
severity grade, season, and geographical ecology; (ii)
dengue vector control measures, including mass larval
control, space spraying (fogging), and health education;
and (iii) serotype patterns of dengue virus from selected
states/regions that were identified in the National
Health Laboratory.
Methods
Study design
This was a cross-sectional descriptive study using
annual records from the Dengue Fever/Dengue
Hemorrhagic Fever (DF/DHF) Prevention and Control
Project in Myanmar.
Setting
General setting
Myanmar is located in the Southeast Asia Region, border-
ing the Republic of China on the north and northeast, Laos
on the east, Thailand on the southeast, Bangladesh on the
west, and India on the northwest. The country is divided
administratively into the Nay Pyi Taw Council Territory
and 14 states and regions and consists of 74 districts, 330
townships, 398 towns, 3065 wards, 13,619 village tracts,
and 64,134 villages. The main geographical features of the
country are the delta region and the central plain sur-
rounded by hills and mountains. Myanmar enjoys a trop-
ical climate with three distinct seasons: hot (February to
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April), wet (May to September), and cool (October to
January) [15]. Myanmar has a population of 51 million
people with an urban-rural population ratio of 30:70. It
has an area of 0.6 million square kilometer and a popula-
tion density of 76 per km2 [15].
Myanmar DF/DHF prevention and control project
In Myanmar, the DF/DHF surveillance program was
launched in 1964 and dengue fever was made a notifi-
able disease in 1966. In 1968, the National Committee
on DHF was formed and the Aedes Mosquito Control
Unit was established. In 1969, sporadic cases of DHF
were recorded in Yangon. The first epidemic of DHF in
Myanmar was recorded in 1970. At that time, the dis-
ease was confined to the Yangon Division only. From
1974 onwards, DHF began to spread to other states and
divisions and the disease is now endemic in all states
and regions (divisions) except Chin State.
The current National DHF Control Strategy has
followed the Asian Pacific Regional Dengue Strategic
Plan (2008–2015) [9]. The major goal is to reduce the
incidence rates of DF and DHF. The main components
of the plan are (i) effective disease and vector surveil-
lance systems based on reliable laboratory and health
information; (ii) disease prevention through selective,
stratified, and integrated vector control with community
education and engagement; (iii) emergency preparedness
to prevent and control outbreaks with appropriate
contingency plans; (iv) prompt case management of DF/
DHF including early recognition of signs and symptoms
to prevent mortality; (v) increased awareness of the
community about DF/DHF prevention, control, and
management through information, education, and commu-
nication; and (vi) improved management and technical
support systems and strengthened health facilities for
health sector development.
Dengue case surveillance Cases that are admitted to
hospital and diagnosed with possible dengue [dengue
fever (DF) and DHF/DSS] based on WHO criteria [11]
are notified to the health department that then intro-
duces dengue source reduction measures as described
below. Case records are kept at the hospital and a focal
person from the VBDC team collects these data on a
weekly basis through fax, electronic mail, and phone
calls. It is estimated that data are collected from 90% or
more of public hospitals in the country. During dengue
outbreaks, the reporting is daily rather than weekly.
These daily or weekly data are collated by focal persons
of the VBDC team with data being transferred upwards
from township to district to state/region and finally to
the Central VBDC Programme at the Department of
Public Health. The Central Programme also reports weekly
to the Ministry of Health and Sports. From the Ministry of
Health and Sports, the reports are sent to WHO SEARO
through the WHO Country Office of Myanmar.
Dengue vector control measures When a new dengue
patient has been identified in an urban ward, the following
measures take place within a 100-m radius from the
patient’s house within 1 week of diagnosis: (i) larval
control: insecticide granules (Temephos) are placed into
domestic and peri-domestic water containers every
3 months in the wet season to kill mosquito larvae; (ii)
mosquito control: space spraying (thermal fogging) using
malathion insecticide; and (iii) health education from the
VBDC teams by conducting health education sessions,
distributing pamphlets, posters, and vinyl printed
materials to the general public and transmitting
information through mass media channels.
Dengue serotypes During an outbreak of dengue, the
National Health Laboratory requests hospitals at
selected regions such as Yangon, Mandalay, Sagaing,
Nay Pyi Taw, Mon, and Tanintharyi to send specimens
from patients with severe complications. Serology was
performed assessing for dengue viral-specific antibodies
using the PAMBIO™ Dengue duo IgM and IgG rapid
strip tests. Conventional PCR was then carried out on
samples testing seropositive to determine the different
serotypes according to the laboratory guidelines. This
process is also carried out every year in children from
the selected regions.
Study sample and population
The study includes all patients diagnosed with dengue in
public hospitals in Myanmar between 2011 and 2015.
The study also includes information on dengue source
reduction measures during the same time period as well
as the pattern of dengue serotypes from patients residing
in selected states/regions.
Variables, data sources, and data collection
Data variables for the study included the following: For
hospital-reported cases of dengue and deaths—year,
month, age group, gender, urban/rural residence, disease
severity grade, season, and ecological area of the country
[16] for each case. The source of data was the VBDC
electronic EXCEL database for aggregate data. For den-
gue vector control measures: (i) larval control—year,
state/region, and coverage in townships, wards, house-
holds, and water containers; (ii) space spraying—year,
state/region, and coverage in townships, wards, house-
holds, and schools; and (iii) health education—year,
number of health education sessions, and number of
people attending health education sessions. The source
of data was the VBDC electronic EXCEL database for
aggregate data from selected states/regions. For dengue
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serotypes—year, samples tested, samples seropositive,
pattern of serotypes (1, 2, 3, or 4). The source of data
was the National Health Laboratory electronic EXCEL
database. The operational definitions for the study vari-
ables are explained in Table 1.
Analysis and statistics
Data were extracted and cleaned in the EXCEL File and
then exported to EpiData software for analysis (version
2.2.2.183, EpiData Association, Odense, Denmark). A
descriptive analysis was performed using frequencies
and proportions. Absolute numbers of dengue cases and
deaths per year were determined and case rates per
100,000 people and dengue case fatality rates per 1000
cases were calculated. Cases and deaths were also ana-
lyzed in relation to age group, gender, urban/rural
residence, disease severity grade, season, and ecological
area of the country. Nationwide spot maps of dengue
cases and deaths across 5 years (2011–2015) by eco-
logical regions were generated through a geographical
information system using Quantum GIS software (ver-
sion 2.18.3, Open source Geospatial Foundation Project).
Results
Hospital-reported cases of dengue and dengue deaths
The annual number of hospital-reported cases of dengue
and associated deaths are shown in Figs. 1 and 2. During
the five-year period, there were a total of 89,832 cases
and 393 deaths. In 2013 and 2015, there was an increase
in number of cases at 21,942 and 42,913, respectively,
while during the other 3 years the number of cases
ranged from 4738 to 13,806. The distribution of dengue
deaths each year mirrored the distribution of cases. The
case fatality rate was highest in 2014 at 7 per 1000
dengue cases, while in the other years, this ranged
between 3 and 5 per 1000 cases.
The demographic and clinical characteristics of all the
hospital-related dengue cases and deaths between 2011
and 2015 are shown in Table 2. Over 95% of all cases
were in children, with those aged 5–9 years being the
predominant age group affected. High case fatality rates
were observed in infants < 1 year and adults ≥ 15 years.
No differences were found in cases or deaths between
males and females or those residing in urban versus
rural settings. The commonest disease severity grade
was DF plus DHF grade 1 (42%), although the majority
of deaths and the highest case fatality occurred in those
with disease severity grade IV.
The seasonal changes and ecological distribution of
hospital-related dengue cases and deaths between 2011
and 2015 are shown in Table 3. The majority of cases
and deaths, with the highest case fatality rates, occurred
in the wet season from May to September. The majority
of cases (85%) and deaths (82%) also occurred in persons
living in the delta region and the plains, although case
fatality was highest in the hills. Figs. 3 and 4 show
dengue cases and deaths in relation to the four
ecological regions of the country. The five main hot
spots for cases were Mon state and the four regions of
Yangon, Ayeyarwady, Mandalay, and Sagaing, and the
main hot spots for death were Yangon followed by
Ayeyarwady region.
Dengue vector control measures and health education
The implementation of dengue vector control measures
in townships, wards, households, and water containers is
shown in Table 4. The implementation of larval control
measures varied from year to year, although coverage
progressively increased at township, ward, and house-
hold levels between 2013 and 2015 (Table 4). The pro-
portion of water containers for which there were
appropriate larval control measures was low at < 10%
coverage in the last 2 years. The implementation of
space spraying as a chemical control measure, especially
during outbreaks progressively increased in townships
and wards between 2012 and 2015, although coverage at
the household and school levels was low, often at < 1%
Table 1 Operational definitions of study variables
SN Variables Operational definitions
1 Ecological regions:
1.1 Delta and lowland (heavy
rainfall more than 2500 mm)
Ayeyarwady, Yangon, and Bago
regions; Mon and Kayin states
1.2 Hills (moderate to heavy
rainfall)
Kachin, Kayah, Chin, and Shan states
1.3 Coastal (heavy rainfall more
than 2500 mm)
Rakhine state and Taninthayi regions
1.4 Plains (uneven topography
and rainfall less than
1000 mm)
Magway, Mandalay, Sagaing,
and Nay Pyi Taw regions
2 Disease severity grade: (WHO
grading of severity of DHF)
2.1 DF Fever with two of the following:
headache, retro-orbital pain,
myalgia, bone pain, rash, and
hemorrhagic manifestations
(No evidence of plasma leakage)
2.2 DHF grade I Fever and hemorrhagic
manifestation (positive tourniquet
test) and evidence of plasma leakage
2.3 DHF grade II As in grade I plus spontaneous
bleeding
2.4 DHF grade III As in grade I or II plus circulatory
failure (weak pulse, narrow pulse
pressure (≤ 20 mmHg), hypotension,
restlessness)
2.5 DHF grade IV As in grade III plus profound shock
with undetectable blood pressure
and pulse
WHO World Health Organization, DF dengue fever, DHF dengue
hemorrhagic fever
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(Table 4). Health education sessions for the general pub-
lic on dengue prevention and control along with num-
bers attending each year are shown in Table 5, the main
findings being a large increase in education sessions and
persons attending these sessions, particularly in 2014
and 2015.
Dengue serotype patterns
Dengue serotype patterns between 2013 and 2015 are
shown in Table 6. In the 2013 outbreak, serotype 1 pre-
dominated, while in the 2015 outbreak, serotypes 1, 2, and
4 predominated.
Discussion
This is the first published study from Myanmar asses-
sing the national burden and characteristics of
hospital-reported dengue cases and deaths over a 5-
year period, describing dengue vector control mea-
sures and health education in the community and
reporting national health laboratory data on serotypes.
There were some interesting findings.
The burden of hospital-recorded cases was high and
mostly concentrated in children. In two of the five
years (2013 and 2015), there were dengue outbreaks,
which are variably defined, but in this context equate
to case numbers that were significantly increased
compared with the previous 5 years [2]. The annual
pattern of dengue deaths mirrored that of cases,
although, interestingly, case fatality was highest in the
2014, the year between the two outbreaks. The rea-
sons for this are not completely clear, but may relate
to the national census being carried out in 2014 pro-
viding more accurate population data and a shift to
dengue virus serotypes 2 and 4 (which were more
common in the 2015 outbreak) and which may be
linked to secondary infections and more severe
disease [17].
With the 5-year data combined, the highest case fatal-
ity was observed in infants and adults (aged 15 years and
above). Unfortunately, in the adult population, the
national information systems only capture those aged
15 years and above with no further stratification, so we
Fig. 1 Annual hospital-reported cases of dengue in Myanmar between 2011 and 2015
Fig. 2 Annual hospital-reported dengue deaths in Myanmar between 2011 and 2015
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do not know which of the older age groups are mainly at
risk. A recent systematic review highlighted the import-
ance of old age and non-communicable diseases, such as
diabetes mellitus, respiratory disease, and renal failure as
risk factors for severe forms of dengue [18], so older
adults may particularly be susceptible to DHF and DSS.
Not surprisingly, disease grade 4 accounted for the
majority of deaths and was associated with the highest case
fatality. The vascular permeability, thrombocytopenia, liver
pathology, complement activation, and altered hemostasis
in severe dengue have been well characterized through aut-
opsy studies on children dying of dengue in Myanmar [19],
but to date, treatment is still supportive effectively with no
specific antiviral agents available for targeted therapy.
The finding that dengue cases were more common in
the wet season and in the delta and lowland regions con-
curs with current knowledge about seasonal transmis-
sion. High temperatures, relative humidity, heavy rainfall
in the wet season, and poor drainage not only assist the
main vector, Aedes aegypti, to multiply and adapt to its
urban environment, but these factors also favor the
propagation of dengue viruses in the mosquito itself
[20–23] Case fatality was higher in the hills, and this
may relate to health facilities being not as well equipped
in these areas, health staff less experienced in the diag-
nosis and management of dengue, and poor immunity of
these populations to the dengue virus [2].
It was encouraging to see the progressive increase
in implementation of larval control measures and
space spraying in townships and wards, particularly
from 2013 to 2015, and this was accompanied by a
similar increase in dengue health education sessions
and the number of people who attended these ses-
sions. Why there was a decrease in vector control
measures between 2011 and 2012 is not clear, but
may have been due to poor community participation
and engagement at this time. Despite the increases in
vector control measures in the most recent years, the
implementation coverage of larval control measures in
households and for water containers that reflected
community participation was still low at less than
25% and space spraying at households and at schools
was even lower at less than 10%. We do not know
whether this reflects the true picture or is an indica-
tor of weak monitoring systems, but clearly, the
intensive vector control efforts over the last few years
did not prevent the dengue outbreak of 2015.
Finally, the serotype data show that dengue serotype 1
predominated in the 2013 outbreak, with all four sero-
types participating in the 2015 outbreak. These findings
accord with previous published studies confirming the
predominance of serotype 1 and the lack of correlation
between serotypes and clinical severity in the 2013 out-
break [24] and the circulation of all four serotypes in the
2015 outbreak [25].
The strengths of this study are the large data set of
hospital-recorded cases and deaths from 90% or more of
public hospitals in the country and dengue source con-
trol measures from selected states/regions, which make
the findings representative of what is happening in the
country. The conduct and reporting of this observational
study are also in line with internationally recommended
Table 2 Demographic and clinical characteristics in relation to
all hospital-reported dengue cases and dengue deaths in
Myanmar between 2011 and 2015
Characteristics Dengue cases Dengue deaths Case fatality
per 1000n (%) n (%)
Total 89,832 (100) 393 (100) 4
Age group in years
< 1 5049 (6) 42 (11) 8
1–4 22,613 (25) 100 (25) 4
5–9 42,186 (47) 187 (48) 4
10–14 17,146 (19) 45 (11) 3
≥ 15 2838 (3) 19 (5) 7
Gender
Male 43,875 (49) 180 (46) 4
Female 45,957 (51) 213 (54) 5
Residence
Urban 43,282 (48) 194 (49) 5
Rural 46,550 (52) 199 (51) 4
Disease severity grade
DF and DHF grade I 37,771 (42) 16 (4) 0
DHF grade II 19,244 (21) 20 (5) 1
DHF grade III 14,285 (16) 44 (11) 3
DHF grade IV 18,532 (21) 313 (80) 17
DF dengue fever, DHF dengue hemorrhagic fever
Table 3 Seasonal changes and the ecological distribution of
hospital-reported dengue cases and dengue deaths in Myanmar
between 2011 and 2015
Characteristics Dengue cases Dengue deaths Case fatality
per 1000n (%) n (%)
Total 89,832 (100) 393 (100) 4
Season:
Hot (February to April) 4424 (5) 12 (3) 3
Wet (May to September) 75,171 (84) 330 (84) 4
Cool (October to January) 10,237 (11) 51 (13) 1
Ecological region:
Delta and lowland 48,412 (54) 205 (52) 4
Hills 5732 (6) 49 (12) 9
Coastal 8327 (9) 24 (6) 3
Plains 27,361 (31) 115 (30) 4
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STROBE guidelines [26]. However, there are a number
of limitations. First, the cases and deaths were all health
facility based, we do not know from the records whether
the dengue cases were based on admission or discharge
diagnoses, and there is no information in our study
about the community burden of dengue or about the
burden of asymptomatic infections. Lack of information
on asymptomatic infections is an important epidemio-
logical gap as a recent study has shown that people with
asymptomatic infections not only infect mosquitoes, but
are more infectious to mosquitoes than those with den-
gue symptoms [27]. Second, we were unable in dengue
cases classified as grade I to differentiate between DF
and DHF. Third, we do not know (as stated earlier)
whether the low implementation coverage of larval
control or space spraying measures in households and
schools or in water containers is a true reflection of what
is happening or whether this relates to weak monitoring,
recording, and reporting. Finally, the data used in the
study were all secondary and collected through the rou-
tine systems, so we have no means of checking accuracy
or validity.
Despite these limitations, there are three important pro-
grammatic implications from this study. First, the health
facility-based reporting of dengue cases and deaths needs
to be revisited to ensure there is functionality at full cap-
acity, the data are collected and transmitted in a timely
way, and through regular supervision, the data are quality
assured. It is also important for the program to collect a
more detailed age-breakdown for those aged 15 years and
Fig. 3 Distribution of all hospital-reported dengue cases in Myanmar between 2011 and 2015
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above and to divide disease severity grade I into DF and
DHF. Whether monitoring can extend to community-
level disease and asymptomatic infection needs fur-
ther discussion, but more accurate measurements
and estimates of disease burden will be essential for
planning vaccination campaigns. Vaccination, in
combination with vector control, is seen as a prom-
ising tool in the fight against dengue. Currently,
there are three candidate live-attenuated vaccines in
phase 2/3 (NIH TV003/TV005 and Takeda TDV vac-
cines) or phase 4 (Sanofi Dengvaxia) trials, although
there are many challenges to overcome before effi-
cacy and safety are assured [28].
Second, there is need to strengthen (a) the monitoring
and (b) recording of vector control measures,
particularly for households, schools, and water con-
tainers. Vector control represents a substantial portion
of government dengue-related costs, and it is important
to note that control of Aedes aegypti is likely to impact
not only on dengue but also on chikungunya and Zika
viruses. The chikungunya virus has been detected in
Myanmar [29, 30], but due to overlap in the clinical
presentation with dengue and cross-reactivity of the
serological tests, the burden of disease in the country
has not been determined. Zika virus was first detected in
a foreign national in Myanmar in 2016 [31], but to date,
there are no published reports of the burden of Zika
virus in the country.
Third, basic science research is crucial to under-
stand more about the virus (serotypes, genotypes, and
Fig. 4 Distribution of all hospital-reported dengue deaths in Myanmar between 2011 and 2015
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strains), the immune responses, the immune corre-
lates of protection and risk, and the development of
dengue vaccines. National programs, however, would
do well to work in partnership with non-governmental
organizations, local community-based organizations, and
self-help groups to ensure better case management,
develop and use point-of-care diagnostics, undertake
timely and accurate surveillance/monitoring and report-
ing, to better engage with the community, to respond to
outbreaks, and to implement source reduction measures
in households as well as in public spaces [28, 32, 33].
More attention also needs to be given to novel biological,
genetic, and behavioral approaches that target mosquitoes
such as the use of Wolbachia bacteria strains that infect
Aedes aegypti mosquitoes [34] and genetically modified
mosquitoes carrying lethal genes [35].
Conclusions
In conclusion, this study has described the large burden
of hospital-recorded dengue in Myanmar between 2011
and 2015, which was concentrated predominately in
children and which included two outbreaks in 2013 and
2015. Case fatality was particularly high in infants aged
less than 1 year, adults aged 15 years or more, patients
with grade IV disease, and those residing in hilly regions
of the country. Implementation and coverage of dengue
vector control measures, including larval control, space
spraying, and health education, all increased between
2012 and 2015, although there are concerns about low
coverage of these interventions in households and
schools. Dengue virus serotype 1 predominated in the
2013 outbreak, while all four serotypes circulated in the
2015 outbreak. Dengue is a serious public health disease
burden in Myanmar. More attention is needed to
improve the monitoring, recording, and reporting of
cases, deaths, and vector control activities, and to avoid
misclassification bias in reporting hospitalized dengue
cases, the notification systems must just report the
discharge diagnosis. Finally, more investment needed for
programmatic research.
Table 4 Annual implementation of dengue vector control measures in Myanmar between 2011 and 2015
Total
numbera
2011 2012 2013 2014 2015
n (%) n (%) n (%) n (%) n (%)
A: larval control measures
Implementation of larval control measures at:
Townships 330 277 (84) 81 (25) 68 (21) 157 (48) 152 (46)
Wards 3065 2655 (87) 931 (30) 1364 (45) 1716 (56) 2026 (66)
Households 10,889,348 2,753,002 (25) 2,191,259 (20) 1,790,151 (16) 2,729,804 (25) 3,447,524 (32)
Water containersb 51,400,000 29,666,676 (58) 5,420,553 (11) 6,755,019 (13) 4,497,076 (9) 10,954,867 (21)
B: space spraying measures
Implementation of space spraying measures at:
Townships 330 120 (36) 15 (5) 68 (21) 84 (25) 158 (48)
Wards 3065 855 (28) 28 (< 1) 478 (16) 1206 (39) 2026 (66)
Households 10,889,348 31,455 (< 1) 39,169 (< 1) 26,293 (< 1) 43,744 (< 1) 410,117 (< 1)
Schools 41,000 305 (< 1) 441 (1) 139 (< 1) 1797 (4) 2568 (6)
aTotal number = total number in the country and is the denominator against which the percentages are calculated
bThe estimated total number of water containers in Myanmar was based on one container per person living in Myanmar. Previous unpublished surveys have
suggested that each resident in the country has one or slightly more than one container with the types of container being drums, cement tanks, ceramic jars,
flower vases, car tires, tins, and coconut shells
Table 5 Annual number of health education sessions about
dengue control measures and numbers attending these
sessions in Myanmar between 2011 and 2015
2011 2012 2013 2014 2015
n n n n n
Health education
sessions
17,928 16,139 6005 72,045 93,664
Persons attending
health education
sessions
2,608,181 1,793,324 2,254,388 3,137,995 4,841,742
Table 6 Dengue serotypes identified each year in Myanmar
between 2011 and 2015
Dengue serum samples
and serotypes
2013 2014 2015
n (%)a n (%)a n (%)a
Total serum samples tested: 230 21 37
Samples seronegative 148 20 1
Samples seropositive: 82 1 36
Serotype 1 44 (54) – 9 (25)
Serotype 2 4 (5) – 11 (31)
Serotype 3 11 (13) 1 (100) 4 (11)
Serotype 4 23 (28) – 12 (33)
aNumbers in percentages are column percentages and refer to serum
samples seropositive
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